Ethyl 5-(3-Chloro-5-fluorophenyl)-5-oxovalerate, 97.0%, 1g

(4S,4'S)-4,4'-Di-tert-butyl-1,1'-di-p-tolyl-4,4',5,5'-tetrahydro-1H,1'H-2,2'-biimidazole, 98%, 250mg

5-Formyl-1-methyl-1H-pyrrole-3-carboxylic acid, 500mg

Obiettivo IOS corretto all'infinito di fase E-Plan EPLPHi S40x/0,65. Distanza di lavoro 0,78 mm

tert-Butyl 3-Ethylpiperazine-1-carboxylate, 97.0%, 25g

2'-Deoxyguanosine 5'-monophosphate (disodium), 500mg

4-(Difluoromethoxy)phenylacetic acid, 95.0%, 10g

3-phenyl-5-pyrrolidin-2-yl-1,2,4-oxadiazole, 95.0%, 250mg

2-Methylthiophene, 98.0%, 500g

3-Bromo-5-(methoxymethyl)benzaldehyde, 98%, 500mg

6-Bromo-7-methyl-[1,2,4]triazolo[1,5-a]pyridine, 95+%, 1g

4-Methylbenzamidine Hydrochloride>98.0%(HPLC)(N)5g

6-Fluoroimidazo[1,5-a]pyridine, 98%, 250mg